C4 Therapeutics Presents Cemsidomide Biomarker Data in Multiple Myeloma
WATERTOWN, Mass. — September 25, 2026 C4 Therapeutics presented new biomarker data from clinical trials of cemsidomide in patients...
Phase 1b
Advertisement
Iterion Therapeutics Reports Positive Tegavivint Phase 1b Data
Houston, Texas, U.S., September 22, 2026 Iterion Therapeutics has announced promising results from a Phase 1b clinical study evaluating...
Kazia Advances Paxalisib in Rare Seizure Disorders
Sydney, Australia, September 21, 2026 Kazia Therapeutics Limited has announced that its development partner Sovargen Co., Ltd. has dosed...
Alkermes Reports Positive Phase 1b ADHD Data for ALKS 7290
DUBLIN — September 21, 2026 Alkermes announced positive topline results from a Phase 1b proof-of-concept study of ALKS 7290,...
Corbus Advances CRB-913 Toward Phase 2 in Obesity
NORWOOD, Mass. — September 14, 2026 Corbus Pharmaceuticals Holdings, Inc. announced positive topline results from its CANYON-1 Phase 1b...
Advertisements
Persica Pharmaceuticals Strengthens PP353 Rationale in Lumbar Back Pain
LONDON, UK — September 11, 2026 Persica Pharmaceuticals Limited published a new methodological analysis examining the sensitivity of microbiology...
Cocrystal Pharma Advances CDI-988 in Norovirus Challenge Study
MIAMI, Fla. and BOTHELL, Wash. — September 9, 2026 Cocrystal Pharma, Inc. announced that the last subject has been...
Faeth Therapeutics Highlights PIKTOR Strategy Ahead of Phase 2 Data
AUSTIN, Texas — September 8, 2026 Faeth Therapeutics announced plans to host a virtual key opinion leader (KOL) event...
Persica Strengthens PP353 Case in Vertebrogenic Back Pain
London, UK — September 4, 2026 Persica Pharmaceuticals Limited announced the publication of new antibiotic exposure-response analyses supporting the...
CRISPR Therapeutics Reports Durable CTX310 Lipid Lowering
Zug, Switzerland & Boston, Mass. – August 28, 2026 CRISPR Therapeutics presented new Phase 1a durability data for CTX310,...
Advertisement
